Madrigal Pharmaceuticals, Inc.
MDGLFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Madrigal Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Madrigal Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-01-20 · Taub Rebecca: Larger than 154 of the 169 other insider sales of Common Stock on file. SEC filing
- 2026-01-09 · FRIEDMAN PAUL A: Larger than 157 of the 169 other insider sales of Common Stock on file. SEC filing
- 2026-01-09 · FRIEDMAN PAUL A: Larger than 156 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · Taub Rebecca: Larger than 163 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · FRIEDMAN PAUL A: Larger than 166 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · Taub Rebecca: Larger than 161 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · FRIEDMAN PAUL A: Larger than 165 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · Taub Rebecca: Larger than 164 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · Taub Rebecca: Larger than 159 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · FRIEDMAN PAUL A: Larger than 168 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-10 · FRIEDMAN PAUL A: Larger than 162 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-12-04 · Sibold William John: Larger than 155 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-11-05 · BATE KENNETH: Larger than 153 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-11-05 · BATE KENNETH: Larger than 160 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-11-05 · BATE KENNETH: Larger than 158 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-09-09 · Sibold William John: Larger than all 169 other insider sales of Common Stock on file. SEC filing
- 2025-08-21 · Sibold William John: Larger than 167 of the 169 other insider sales of Common Stock on file. SEC filing
- 2025-08-20 · BAKER JULIAN: Larger than 23 of the 24 other insider purchases of Common Stock on file. SEC filing
- 2025-08-18 · BAKER JULIAN: Larger than all 24 other insider purchases of Common Stock on file. SEC filing
- 2025-08-18 · BAKER JULIAN: Larger than 22 of the 24 other insider purchases of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-01 | Soergel David · Chief Medical Officer | Common Stock | S — Open market or private sale | −1,042 | 495.74 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −320 | 508.24 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −151 | 510.36 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −439 | 512.50 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −1,497 | 517.59 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −40 | 506.68 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −657 | 515.92 | SEC filing |
| 2026-05-22 | Levy Richard S · Director | Common Stock | S — Open market or private sale | −80 | 519.98 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | FOUSE JACQUALYN A · Director | Common Stock | A — Grant, award, or other acquisition | +454 | SEC filing |
| 2026-06-17 | FOUSE JACQUALYN A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +766 | SEC filing |
| 2026-06-17 | Levy Richard S · Director | Common Stock | A — Grant, award, or other acquisition | +454 | SEC filing |
| 2026-06-17 | Daly James M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +766 | SEC filing |
| 2026-06-17 | Taub Rebecca · Director | Common Stock | A — Grant, award, or other acquisition | +454 | SEC filing |
| 2026-06-17 | Brennan Daniel J. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +681 | SEC filing |
| 2026-06-17 | BAKER JULIAN · Director | Common Stock | A — Grant, award, or other acquisition | +908 | SEC filing |
| 2026-06-17 | BAKER JULIAN · Director | Non-Qualified Stock Options (right to buy) | A — Grant, award, or other acquisition | +1,532 | SEC filing |
Showing 8 of 21 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.